4 news items
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
DAWN
18 Jun 24
. DAY ONE MEDIALaura Cooper, Head of Communications
Day One Announces Sale of Priority Review Voucher for $108 Million
DAWN
30 May 24
Cooper, Head of Communications
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
DAWN
6 May 24
here in the U.S., and we are grateful to the members of the pediatric brain tumor community whose support of the program has been invaluable," said
Day One's OJEMDAâ„¢ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN
23 Apr 24
first approved medicine addresses this serious and life-threatening disease of childhood and adolescence. We are grateful to the pLGG community
- Prev
- 1
- Next